Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome
December 13, 2018 11:09 AM EST
H.C. Wainwright analyst Andrew Fein lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $102.00 (from $162.00) while maintaining a Buy rating.
...
More
December 13, 2018 9:30 AM EST
Oppenheimer analyst Jay Olson lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $105.00 (from $140.00) while maintaining a Outperform rating.
Olson commented, "T-Force-GOLD missed the primary endpoint, sending NBIX shares down 14% on 12/12 (vs. NBI +1.3% and S&P 500 +0.5%) on the loss of this important... More
December 12, 2018 12:16 PM EST
Baird analyst Brian Skorney lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $96.00 (from $131.00) while maintaining an Outperform rating and removed the Fresh Pick designation on Tourette failure.
As a result, the firm is reducing their peak sales estimate for... More
December 12, 2018 10:48 AM EST
Needham & Company analyst Alan Carr lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $104.00 (from $125.00) while maintaining a Buy rating.
Carr commented, "Neurocrine announced that the Phase 2b/3 T-Force GOLD trial of Ingrezza in Tourette Syndrome did not meet primary... More
December 12, 2018 7:34 AM EST
Neurocrine Biosciences (NASDAQ: NBIX) to Resume Trading at 8 am ET
...
More
